This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    SC-104
Previous Study | Return to List | Next Study

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05256381
Recruitment Status : Active, not recruiting
First Posted : February 25, 2022
Last Update Posted : March 8, 2024
Sponsor:
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Sotio Biotech Inc. ( SOTIO Biotech AG )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Colorectal Cancer Cutaneous Squamous Cell Carcinoma Hepatocellular Carcinoma Castration-resistant Prostate Cancer Ovarian Cancer Drug: Nanrilkefusp Alfa Drug: Pembrolizumab Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors
Actual Study Start Date : June 21, 2022
Estimated Primary Completion Date : April 1, 2025
Estimated Study Completion Date : July 30, 2025

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Nanrilkefusp Alfa and Pembrolizumab
Participants will be treated with 12 μg/kg of nanrilkefusp alfa on Day 1, Day 2, Day 8, and Day 9 of each 3-week cycle in combination with 200 mg pembrolizumab on Day 1 of each 3-week cycle.
 Drug: Nanrilkefusp Alfa
Subcutaneous (SC) injection.
Other Name: SOT101

Drug: Pembrolizumab
Intravenous (IV) infusion via peripheral or central venous line.
Other Name: KEYTRUDA®


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) [ Time Frame: Day 1 up to approximately 3 years ]

Secondary Outcome Measures :
  1. Number of Participants with a Treatment-emergent Adverse Event (TEAE) [ Time Frame: Day 1 up to approximately 3 years ]
  2. Number of Participants with an Adverse Event of Special Interest (AESI) [ Time Frame: Day 1 up to approximately 3 years ]
  3. Immune ORR (iORR) According to RECIST for immune-based therapeutics (iRECIST) [ Time Frame: Day 1 up to approximately 3 years ]
  4. Best Overall Response (BOR) According to RECIST 1.1 [ Time Frame: Day 1 up to approximately 3 years ]
  5. Immune BOR (iBOR) According to iRECIST [ Time Frame: Day 1 up to approximately 3 years ]
  6. Duration of Response (DoR) According to RECIST 1.1 [ Time Frame: Day 1 up to approximately 3 years ]
  7. Immune DoR (iDoR) According to iRECIST [ Time Frame: Day 1 up to approximately 3 years ]
  8. Clinical Benefit Rate (CBR) According to RECIST 1.1 [ Time Frame: Day 1 up to approximately 3 years ]
  9. Immune CBR (iCBR) According to iRECIST [ Time Frame: Day 1 up to approximately 3 years ]
  10. Progression-free Survival (PFS) According to RECIST 1.1 [ Time Frame: Day 1 up to approximately 3 years ]
  11. Immune PFS (iPFS) According to iRECIST [ Time Frame: Day 1 up to approximately 3 years ]
  12. Time to Response (TtR) According to RECIST 1.1 [ Time Frame: Day 1 up to approximately 3 years ]
  13. Immune TtR (iTtR) According to iRECIST [ Time Frame: Day 1 up to approximately 3 years ]
  14. Metastatic Castration-resistant Prostate Cancer (mCRPC) only: DoR as Assessed According to Prostate Cancer Clinical Trials Working Group 3 (PCWG3)-modified RECIST 1.1 [ Time Frame: Day 1 up to approximately 3 years ]
  15. mCRPC only: CBR as Assessed According to PCWG3-modified RECIST 1.1 [ Time Frame: Day 1 up to approximately 3 years ]
  16. mCRPC only: PFS as Assessed According to PCWG3-modified RECIST 1.1 [ Time Frame: Day 1 up to approximately 3 years ]
  17. mCRPC only: Circulating Tumor Cell (CTC) Count Conversion as Assessed According to PCWG3-modified RECIST 1.1 [ Time Frame: Day 1 up to approximately 2 years ]
  18. mCRPC only: Confirmed Prostate-specific Antigen (PSA) Decline of ≥50% as Assessed According to PCWG3-modified RECIST 1.1 [ Time Frame: Day 1 up to approximately 2 years ]
  19. mCRPC only: Time to Confirmed PSA Progression as Assessed According to PCWG3-modified RECIST 1.1 [ Time Frame: Day 1 up to approximately 2 years ]
  20. Nanrilkefusp Alfa Concentration Profile at Various Timepoints [ Time Frame: Cycle 1 Day 1 to Cycle 3 Day 1 (up to approximately 9 weeks, where each cycle is 3 weeks) ]
  21. Number of Participants with Anti-drug Antibodies (ADAs) [ Time Frame: Day 1 up to approximately 2 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants with the following histologically or cytologically confirmed solid tumor indications and line of treatment:

    1. Non-small cell lung cancer (NSCLC).
    2. Colorectal cancer.
    3. Cutaneous squamous cell carcinoma (cSCC).
    4. Advanced hepatocellular carcinoma (not applicable in France).
    5. mCRPC.
    6. Ovarian cancer.
  • Have measurable disease per RECIST 1.1. mCRPC participants with no measurable disease and only widespread bone disease must have a CTC count of ≥5 cells per 7.5 mL of blood.
  • Availability of tumor tissue from a fresh biopsy at screening unless the biopsy cannot be obtained due to safety reasons or non-accessibility of the tumor site. If it is not possible to obtain a fresh biopsy, every effort should be taken to retrieve an archival biopsy. Archived, fixed tumor tissue may only be collected if taken preferentially after completion of the most recent systemic tumor therapy and within 12 months prior to the first dose of study treatment.
  • Eastern Cooperative Oncology Group (ECOG) score 0-1.
  • Have recovered from all AEs (except alopecia) due to previous therapies to grade ≤1 (excluding alopecia) or have stable grade 2 neuropathy.

  • Have adequate organ function as defined below:

    1. Hematology:

      1. Absolute neutrophil count ≥1500/μL.
      2. Platelets ≥100 000/μL.
      3. Hemoglobin ≥9.0 g/dL .
    2. Renal function: Creatinine clearance as measured by glomerular filtration rate ≥30 mL/min using Cockcroft-Gault equation.
    3. Hepatic function: Alanine transaminase (ALT)/aspartate transaminase (AST) ≤2.5× upper limit of normal (ULN) and total bilirubin ≤1.5×ULN or direct bilirubin ≤ ULN in participants without liver metastasis. In participants with liver metastasis, ALT/AST ≤5×ULN is allowed but total bilirubin must be ≤2×ULN.
    4. Prothrombin time and activated partial thromboplastin time ≤1.5×ULN.
  • Participants must not have active hepatitis B or hepatitis C infection.
  • Adequate contraception must be applied in all women of childbearing potential (WOCBP) and in male participants.

Exclusion Criteria:

  • Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a grade ≥3 AE.
  • Prior exposure to agonists of interleukin (IL)-2 or IL-15.

  • Prior systemic anti-cancer therapies, including investigational agents:

    1. Less than 4 weeks for systemic chemotherapy and immuno-oncology therapies; and for tyrosine kinase inhibitors 4 weeks or 5 half-lives (whichever is shorter).
    2. Less than 4 weeks from major surgeries and not recovered adequately.
  • Has received prior radiotherapy within 2 weeks of the start of study interventions or have had a history of radiation pneumonitis.
  • NSCLC indication only: Received radiation therapy to the lung >30 Gy within 6 months.
  • Has received a live or live-attenuated vaccine within 30 days.

  • Clinically significant cardiac abnormalities including prior history of any of the following:

    1. Cardiomyopathy, with left ventricular ejection fraction ≤ 50%.
    2. Congestive heart failure of New York Heart Association grade ≥2.
    3. History of clinically significant artery or coronary heart disease.
    4. Prolongation of QTcF >450 msec .
    5. Clinically significant cardiac arrythmia that cannot be controlled with adequate medication.
  • Uncontrolled hypertension defined as systolic blood pressure >160 mmHg, diastolic blood pressure >110 mmHg.
  • Prior allogeneic hematopoietic stem cell transplantation within the last 5 years.
  • Prior allogeneic tissue/solid organ transplant.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy.
  • History of or serology positive for human immunodeficiency virus (HIV).
  • Has a known additional malignancy that is progressing or has required active treatment within the past 5 years, except for basal cell carcinoma of the skin or carcinoma in situ that have undergone potentially curative therapy are not excluded.
  • Has known active central nervous system metastases and/or carcinomatous meningitis, unless stable.
  • Had severe hypersensitivity (grade ≥3) to pembrolizumab and/or any of its excipients.
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years.
  • History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
  • Has an active infection requiring systemic therapy.
  • Has any condition that might confound the results of the study or interfere with the participant's participation for the full duration of the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05256381


Locations
Show Show 52 study locations
Sponsors and Collaborators
SOTIO Biotech AG
Merck Sharp & Dohme LLC
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: SOTIO Biotech AG
ClinicalTrials.gov Identifier: NCT05256381    
Other Study ID Numbers: SC104
KEYNOTE-D13 ( Other Identifier: Merck Sharp & Dohme )
AURELIO-04 ( Other Identifier: SOTIO Biotech AG )
2021-005774-25 ( EudraCT Number )
MK-3475-D13 ( Other Identifier: Merck Sharp & Dohme )
First Posted: February 25, 2022    Key Record Dates
Last Update Posted: March 8, 2024
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sotio Biotech Inc. ( SOTIO Biotech AG ):
SOT101
SO-C101
Pembrolizumab
Non-Small Cell Lung Cancer
Colorectal Cancer
Cutaneous Squamous Cell Carcinoma
 Advanced Hepatocellular Carcinoma
Metastatic Castration-resistant Prostate Cancer
Ovarian Cancer
KEYNOTE-D13
AURELIO-04
Nanrilkefusp Alfa
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Prostatic Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Carcinoma, Squamous Cell
Carcinoma, Hepatocellular
Ovarian Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
 Respiratory Tract Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Prostatic Diseases
Male Urogenital Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases